Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Comorbid

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44347   clinical trials with a EudraCT protocol, of which   7375   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    125 result(s) found for: Comorbid. Displaying page 3 of 7.
    « Previous 1  2  3  4  5  6  7  Next»
    EudraCT Number: 2010-021884-34 Sponsor Protocol Number: PERS3 Start Date*: 2013-01-24
    Sponsor Name:Radboud University Medical Centre Nijmegen
    Full Title: Relapse prevention in children and adolescents with DSM-IV Conduct Disorder treated with Risperidone: a Randomized Double blind, Placebo-Controlled, Discontinuation Study.
    Medical condition: Conduct Disorder DSM-IV-TR; 312.8x, APA 2000
    Disease: Version SOC Term Classification Code Term Level
    14.1 10037175 - Psychiatric disorders 10064478 Conduct disorder PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed) DE (Ongoing) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-007157-12 Sponsor Protocol Number: CNTO328MMY2001 Start Date*: 2009-05-12
    Sponsor Name:Centocor BV
    Full Title: Estudio Fase II aleatorizado y abierto de CNTO328 (anticuerpo monoclonal anti-IL-6) y VELCADE-Melfalán-Prednisona comparado con Velcade-Melfalán-Prednisona para el tratamiento del Mieloma Múltiple ...
    Medical condition: Mieloma Múltiple Sintomático
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-000829-27 Sponsor Protocol Number: LPS16747 Start Date*: 2021-09-23
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, head-to-head comparison of dupilumab versus omalizumab in severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and comorbid asthma patients
    Medical condition: Chronic rhinosinusitis with nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    20.1 10038738 - Respiratory, thoracic and mediastinal disorders 10080060 Chronic rhinosinusitis with nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) DE (Completed) BE (Completed) CZ (Completed) FI (Completed) HU (Completed) SE (Completed) ES (Ongoing) DK (Completed) PT (Completed) PL (Completed) IT (Completed) RO (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-000909-28 Sponsor Protocol Number: 64007957MMY3005 Start Date*: 2022-09-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination with Daratumumab SC and Lenalidomide (Tal-DR) versus Dar...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Trial now transitioned) ES (Ongoing) FR (Trial now transitioned) NL (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) CZ (Trial now transitioned) AT (Trial now transitioned) NO (Trial now transitioned) PL (Trial now transitioned) DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-003450-16 Sponsor Protocol Number: WA40169 Start Date*: 2018-06-04
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: OPEN-LABEL EXTENSION STUDY OF OMALIZUMAB IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPS
    Medical condition: Chronic rhinosinusitis with nasal polyps
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10028756 Nasal polyps PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) PT (Completed) FI (Completed) CZ (Completed) BE (Completed) DE (Completed) HU (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003867-87 Sponsor Protocol Number: ID-078A205 Start Date*: 2022-10-04
    Sponsor Name:Idorsia Pharmaceuticals Ltd
    Full Title: Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Polysomnography, Dose-finding Study Assessing the Efficacy, Safety, and Pharmacokinetics of Multiple-dose Oral Administra...
    Medical condition: Insomnia Disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Ongoing) BG (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2014-002272-88 Sponsor Protocol Number: 54767414MMY3007 Start Date*: 2014-10-20
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination with VMP (D-VMP), in Subjects with Previously Untreated...
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) ES (Completed) CZ (Completed) IT (Completed) DE (Completed) BG (Completed) RO (Ongoing) PL (Completed) HR (Completed) GR (Completed) PT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001490-15 Sponsor Protocol Number: RIS-BMN-3001 Start Date*: 2007-04-23
    Sponsor Name:Janssen-Cilag International N.V
    Full Title: A randomized, double-blind, placebo- and active-controlled, parallel-group study to evaluate the efficacy and safety of risperidone long-acting injectable for the prevention of mood episodes in the...
    Medical condition: Subjects with a diagnosos of bipolar I disorder who are currently experiencing a manic or mixed episode (YMRS>20 and CGI-S>/= 4 [moderate]) or who are between mood episodes (non-acute; YMRS<12 and ...
    Disease: Version SOC Term Classification Code Term Level
    8.1 10004939 Bipolar I disorder LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2019-000419-98 Sponsor Protocol Number: B4Z-US-LYEI Start Date*: 2021-12-13
    Sponsor Name:Eli Lilly and Company
    Full Title: Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tas...
    Medical condition: Attention Deficit Hyperactivity Disorder, Dyslexia.
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004873 10003735 Attention deficit-hyperactivity disorder LLT
    20.0 10029205 - Nervous system disorders 10013932 Dyslexia PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2018-005027-16 Sponsor Protocol Number: NOA-18 Start Date*: 2020-09-16
    Sponsor Name:Heidelberg University Hospital Represented in law by its Commercial Managing Director
    Full Title: Improvement of functional Outcome for patients with newly diagnosed grade 2 or 3 glioma with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial
    Medical condition: WHO grade 2 or 3 glioma
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10018338 Glioma PT
    20.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10030288 Oligodendroglioma malignant LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-003117-35 Sponsor Protocol Number: EFC16723 Start Date*: 2021-03-17
    Sponsor Name:Sanofi-aventis Recherche & Développement
    Full Title: A randomized, double-blind, placebo-controlled, 2-part study to evaluate the efficacy and safety of dupilumab in patients with uncontrolled, chronic rhinosinusitis without nasal polyposis (CRSsNP)
    Medical condition: Chronic rhinosinusitis without nasal polyposis
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10009137 Chronic sinusitis PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) SE (Completed) HU (Completed) PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-020147-12 Sponsor Protocol Number: B1931008 Start Date*: 2011-02-16
    Sponsor Name:Pfizer Inc
    Full Title: AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF INOTUZUMAB OZOGAMICIN ADMINISTERED IN COMBINATION WITH RITUXIMAB COMPARED TO DEFINED INVESTIGATOR’S CHOICE THERAPY IN SUBJECTS WITH RELAPSED OR REFRACTOR...
    Medical condition: Aggressive Non-Hodgkin Lymphoma (NHL)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029547 Non-Hodgkin's lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) SE (Completed) ES (Completed) DE (Completed) GB (Completed) HU (Completed) LT (Completed) BG (Completed) BE (Completed) GR (Completed) NL (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2021-001242-35 Sponsor Protocol Number: 68284528MMY3004 Start Date*: 2021-08-02
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 3 Randomized Study Comparing Bortezomib, Lenalidomide and Dexamethasone (VRd) followed by Ciltacabtagene Autoleucel, a Chimeric Antigen Receptor T cell (CAR-T) Therapy Directed Against BCMA...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Trial now transitioned) SE (Trial now transitioned) DK (Trial now transitioned) FR (Trial now transitioned) PL (Trial now transitioned) NO (Trial now transitioned) DE (Trial now transitioned) PT (Trial now transitioned) FI (Trial now transitioned) NL (Ongoing) CZ (Trial now transitioned) ES (Ongoing) HU (Ongoing) AT (Trial now transitioned) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2011-006292-20 Sponsor Protocol Number: GS-US-312-0115 Start Date*: 2012-07-20
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chroni...
    Medical condition: Chronic Lymphocytic Leukemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) ES (Completed) IT (Completed) PL (Completed) CZ (Completed) HU (Completed) DE (Completed) IE (Completed) PT (Completed) GR (Completed) HR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002002-20 Sponsor Protocol Number: 2014METAL1 Start Date*: 2015-06-10
    Sponsor Name:UMCG
    Full Title: A multicentre randomized double-blind placebo controlled discontinuation trial of methylphenidate
    Medical condition: attention-deficit/hyperactivity disorder
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-020764-38 Sponsor Protocol Number: A8241012 Start Date*: 2010-12-14
    Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017, US
    Full Title: PHASE 2, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, 4-WEEK INPATIENT STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TWO FIXED DOSES OF PF-02545920 COMPARED TO PLACEBO IN THE TREATMENT OF ...
    Medical condition: Schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    12.1 10009134 Chronic schizophrenia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004271-78 Sponsor Protocol Number: CIAOII Start Date*: 2016-05-31
    Sponsor Name:King's College London
    Full Title: Randomised controlled trial of the short term effects of OROS-methylphenidate on ADHD symptoms and behavioural outcomes in young male prisoners with attention deficit hyperactivity disorder
    Medical condition: Attention Deficit Hyperactivity Disorder (ADHD)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004873 10064104 ADHD LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001718-26 Sponsor Protocol Number: DFI10560 Start Date*: 2010-05-07
    Sponsor Name:Sanofi-Aventis Recherche & Développement
    Full Title: An eight-week, multicenter, randomized, double-blind, placebo-controlled dose-finding study, with escitalopram (10mg daily) as active control, to evaluate the efficacy, safety and tolerability of t...
    Medical condition: Major Depressive Disorder
    Disease: Version SOC Term Classification Code Term Level
    11.0 10025453 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SK (Completed)
    Trial results: View results
    EudraCT Number: 2019-001023-13 Sponsor Protocol Number: Ox_Psych_PAXD Start Date*: 2019-11-11
    Sponsor Name:University of Oxford / Clinical Trials and Research Governance
    Full Title: PAX-D: Randomised placebo-controlled trial evaluating the efficacy and mechanism of pramipexole as add-on treatment for people with treatment resistant depression
    Medical condition: Treatment resistant depression
    Disease: Version SOC Term Classification Code Term Level
    21.1 10037175 - Psychiatric disorders 10057840 Major depression PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003651-54 Sponsor Protocol Number: 2014RISP1 Start Date*: 2015-10-14
    Sponsor Name:UMCG
    Full Title: ‘Off-label use of Risperidone in Children and Adolescents (ORCA): a double-blind placebo-controlled discontinuation trial’
    Medical condition: no specific condition, we will investigate children who have been using risperidone on an off-label basis for at least one year.
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  4  5  6  7  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Jul 03 18:14:17 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA